Biogen (NASDAQ:BIIB – Get Free Report) had its price objective lifted by equities research analysts at Mizuho from $221.00 to $241.00 in a research report issued on Tuesday,Benzinga reports. The Goldman Sachs Group raised their target price on shares of Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Morgan Stanley lifted their price target on Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Finally, Guggenheim lifted their target price on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st.